Natroba (Spinosad) Patent Expiration, LOE Window & CMS Spending

Natroba (Spinosad) by Cipher: FDA Orange Book LOE 2033-11-25, 0 AB generics, $52.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCipher
FDA Application & PathwayN022408 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-11-25
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$52.7M
2024 Medicare Part D Spend$161K
2024 Medicaid Spend$52.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel